"
Team:UCL London/Manufacturing/PurityYieldCost
From 2011.igem.org
| Line 14: | Line 14: | ||
Dosage: expected to be 0.5 to 5 μg per dose, 5mg per full course [3] [4]<br /> | Dosage: expected to be 0.5 to 5 μg per dose, 5mg per full course [3] [4]<br /> | ||
Product titre: DNA yield approximately 200 mg/L in fermentor [5] | Product titre: DNA yield approximately 200 mg/L in fermentor [5] | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
</div> | </div> | ||
{{:Team:UCL_London/Template/Footer}} | {{:Team:UCL_London/Template/Footer}} | ||
Revision as of 22:02, 21 September 2011
Introduction
As discussed in the medical session, DNA vaccine technology has created the potential for a broad variety of human diseases including cancer. The development of DNA vaccines has entered into human clinical trials stage. In order to study the impact of our project, E.coili, on DNA vaccine industry, we have done a case study based on DNA vaccine for certain types of cancer. The results clearly show the improvement in terms of yield, purity, processing time and cost by using cell as a factory with the application of synthetic biology.
Market research:
Target diseases: Breast/Colorectal/Ovarian/Lung cancer [1]
Incidence: 570,000annual incidences in US, estimated to be 1,000,000 treatments per year [1]
Potential market size: estimated to be $17 billion in North America, $45 billion world wide [2]
Average cost: $30,000 per course [1]
Dosage: expected to be 0.5 to 5 μg per dose, 5mg per full course [3] [4]
Product titre: DNA yield approximately 200 mg/L in fermentor [5]
